Therefore, in the guidelines and consensus on diabetes prevention and treatment of various countries, SGLT-2 inhibitors are recommended for the treatment of T2DM patients with established cardiovascular disease or high risk of cardiovascular disease. The gene discussed is SLC5A2; the disease is cardiovascular disorder.